Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd (SHE:301130)
China · Delayed Price · Currency is CNY 28.51
+0.53 (1.89%)
Sep 30, 2026, 3:04 PM CST
SHE:301130 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 2,152 | 2,183 | 2,009 | 2,253 | 2,333 | - | |
Market Cap Growth | -4.97% | 8.65% | -10.80% | -3.43% | - | - |
Enterprise Value | 1,998 | 1,980 | 1,650 | 1,699 | 1,718 | - |
Last Close Price | 28.51 | 28.39 | 25.88 | 27.19 | 27.99 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 365.88 | 99.69 | 49.90 | 44.61 | 57.29 | - |
PS Ratio | 10.35 | 9.30 | 7.84 | 9.99 | 9.13 | - |
PB Ratio | 2.39 | 2.34 | 2.13 | 2.29 | 2.47 | - |
P/TBV Ratio | 3.05 | 2.81 | 2.59 | 2.35 | 2.54 | - |
P/FCF Ratio | - | - | - | - | 181.84 | - |
P/OCF Ratio | 50.50 | 44.90 | 37.04 | 41.42 | 34.70 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 9.61 | 8.43 | 6.44 | 7.53 | 6.72 | - |
EV/EBITDA Ratio | 53.50 | 39.00 | 27.51 | 37.49 | 31.36 | - |
EV/EBIT Ratio | - | 126.11 | 43.93 | 63.47 | 47.35 | - |
EV/FCF Ratio | - | - | - | - | 133.89 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.04 | 0.01 | 0.01 | 0 | - | - |
Debt / EBITDA Ratio | 1.07 | 0.23 | 0.17 | 0.01 | - | - |
Net Debt / Equity Ratio | -0.20 | -0.24 | -0.28 | -0.56 | -0.65 | -0.41 |
Net Debt / EBITDA Ratio | -4.96 | -4.43 | -4.43 | -12.14 | -11.25 | -3.21 |
Net Debt / FCF Ratio | 8.54 | 12.89 | 3.29 | 8.00 | -48.02 | -5.69 |
Asset Turnover | 0.20 | 0.22 | 0.24 | 0.22 | 0.32 | 0.50 |
Inventory Turnover | 1.91 | 2.03 | 2.21 | 1.89 | 2.01 | 2.01 |
Quick Ratio | 2.77 | 3.33 | 4.26 | 11.23 | 17.45 | 7.99 |
Current Ratio | 3.33 | 3.88 | 4.71 | 11.80 | 18.18 | 9.08 |
Return on Equity (ROE) | 0.46% | 2.12% | 4.19% | 5.24% | 5.54% | 10.44% |
Return on Assets (ROA) | -0.23% | 0.92% | 2.21% | 1.60% | 2.81% | 5.27% |
Return on Invested Capital (ROIC) | -0.55% | 2.15% | 5.87% | 6.08% | 9.18% | 14.02% |
Return on Capital Employed (ROCE) | -0.40% | 1.60% | 3.80% | 2.60% | 3.70% | 8.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 0.27% | 1.00% | 2.00% | 2.24% | 1.75% | - |
FCF Yield | -1.00% | -0.80% | -4.02% | -3.05% | 0.55% | - |
Dividend Yield | 0.51% | 0.51% | 1.00% | 0.96% | 0.57% | - |
Payout Ratio | 195.03% | 92.76% | 49.70% | 25.60% | 25.80% | - |
Buyback Yield / Dilution | -0.72% | 1.74% | 3.66% | -4.35% | -27.78% | 0.00% |
Total Shareholder Return | -0.21% | 2.25% | 4.67% | -3.40% | -27.21% | 0.00% |